Experience

Opthea

• Australia
• Biotechnology Research
• 1 - 100 Employee

• VP, Strategy & Corporate Development

  • Nov 2023 - 2 months

  Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of… Show more Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone. Show less



Graybug Vision, Inc.

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director, Business Development and Alliance Management

  • Oct 2021 - Mar 2023

  Primary responsibilities as direct report to CEO: global business development (in- and out-licensing), strategic partnerships, post-transaction integration, portfolio strategy and business planning, investor communications, special projects for executive leadership team and Board of Directors. Graybug was a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. (Graybug merged with CalciMedica, a clinical-stage biopharmaceutical… Show more Primary responsibilities as direct report to CEO: global business development (in- and out-licensing), strategic partnerships, post-transaction integration, portfolio strategy and business planning, investor communications, special projects for executive leadership team and Board of Directors. Graybug was a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. (Graybug merged with CalciMedica, a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need.)

• Director, Corporate Development and Strategy

  • Sep 2020 - Oct 2021



Corium

• United States
• Pharmaceutical Manufacturing
• 300 - 400 Employee

• Senior Analyst, Strategic Projects

  • Jun 2015 - Sep 2020

  Primary responsibilities as direct report to CFO: long-range financial planning and scenario modeling, international joint venture structuring (Germany), portfolio strategy, business development, investor relations and roadshows, private debt structuring and public debt/equity financings. Corium is a commercial-stage biopharmaceutical company focused on the development, manufacture, and commercialization of specialty pharmaceutical products that leverage the company's broad experience… Show more Primary responsibilities as direct report to CFO: long-range financial planning and scenario modeling, international joint venture structuring (Germany), portfolio strategy, business development, investor relations and roadshows, private debt structuring and public debt/equity financings. Corium is a commercial-stage biopharmaceutical company focused on the development, manufacture, and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems.

• Financial Analyst

  • Jul 2014 - Jun 2015